Description: Pradigastat sodium (LCQ908ABA; LCQ 908 sodium) is an orally bioavailable diacylglycerol acyltransferase 1 (DGAT1) inhibitor being developed for the treatment of familial chylomicronemia syndrome. It is also being studied in phase II clinical trials as an anti-obesity and anti-diabetic agent. Familial chylomicronemia syndrome (FCS) is a rare lipid disease caused by complete lipoprotein lipase (LPL) deficiency resulting in fasting chylomicronemia and severe hypertriglyceridemia. Inhibition of diacylglycerol acyltransferase 1 (DGAT1), which mediates chylomicron triglyceride (TG) synthesis, is an attractive strategy to reduce TG levels in FCS .

References: Curr Opin Drug Discov Devel. 2010 Jul;13(4):489-96.